NasdaqCM:ATYRBiotechs
aTyr Pharma (ATYR): Evaluating Valuation Following New Efzofitimod Data and Securities Lawsuit
aTyr Pharma (ATYR) is drawing attention after presenting fresh Phase 3 results for its lead drug candidate, efzofitimod, at a major medical conference. The company also faces a newly filed securities class action lawsuit.
See our latest analysis for aTyr Pharma.
After a rocky stretch, aTyr Pharma’s recent ERS Congress presentation sparked renewed attention and contributed to a sharp 36.7% 7-day share price rebound, even as the stock remains down 72.9% this year. While the 1-year total...